Layfield Lester J, Baloch Zubair W, Esebua Magda, Kannuswamy Rohini, Schmidt Robert L
Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, USA.
Acta Cytol. 2017;61(3):187-193. doi: 10.1159/000469654. Epub 2017 Apr 27.
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established diagnostic categories for cytologic specimens of the thyroid. Each category was associated with an estimated risk of malignancy. Recently, the non-invasive follicular variant of papillary thyroid carcinoma has been reclassified as benign. This reclassification may alter the malignancy risk of TBSRTC diagnostic categories.
A literature search was made for all studies investigating the effect of reclassification of some non-invasive follicular variant papillary thyroid carcinomas as benign on the malignancy risk associated with TBSRTC categories. The authors calculated the malignancy risk for TBSRTC categories in a series of 315 thyroid aspirates when the non-invasive follicular variant of papillary thyroid carcinoma was considered benign. A meta-analysis of malignancy risk data for the 3 published studies and the current study was performed.
The meta-analysis showed that the malignancy risk was reduced for all TBSRTC categories except the "non-diagnostic" category. The reduction in malignancy risk was greatest in the categories "suspicious for malignancy" and "atypia/follicular lesion of undetermined significance."
A meta-analysis of all pertinent studies demonstrated that re-categorization of the non-invasive follicular variant of papillary thyroid carcinoma as benign reduces the malignancy risk in the majority of TBSRTC categories.
甲状腺细胞病理学报告的贝塞斯达系统(TBSRTC)为甲状腺细胞标本建立了诊断类别。每个类别都与估计的恶性风险相关。最近,甲状腺乳头状癌的非侵袭性滤泡变体已被重新分类为良性。这种重新分类可能会改变TBSRTC诊断类别的恶性风险。
对所有研究进行文献检索,这些研究调查了将一些甲状腺乳头状癌的非侵袭性滤泡变体重新分类为良性对与TBSRTC类别相关的恶性风险的影响。作者计算了在315例甲状腺细针穿刺抽吸物中,当甲状腺乳头状癌的非侵袭性滤泡变体被视为良性时,TBSRTC类别的恶性风险。对3项已发表研究和本研究的恶性风险数据进行了荟萃分析。
荟萃分析表明,除“无法诊断”类别外,所有TBSRTC类别的恶性风险均降低。“可疑恶性”和“意义未明的不典型/滤泡性病变”类别中恶性风险的降低最大。
对所有相关研究的荟萃分析表明,将甲状腺乳头状癌的非侵袭性滤泡变体重新分类为良性可降低大多数TBSRTC类别的恶性风险。